September 2023 Snap Recap: Prostate Cancer Awareness, Breast Cancer QOL Insights

News
Video

In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.

As we enter the final leg of 2023, CancerNetwork® looks back on the biggest news pieces of September as decided on by our readers. Popular selections included articles on the clearance of an investigational new drug application for a CDK12/13 inhibitor, the quality-of-life benefits of a certain diet and exercise intervention in breast cancer, how AI may help with diagnosis and risk stratification in prostate cancer, the impact of adaptive stereotactic body radiotherapy on toxicities in prostate cancer, and recurrence risk following breast-conserving surgery and endocrine therapy for luminal breast cancer.1-4

Full versions of the article are referenced below in the order that they appear in the show:

References

  1. Carrick Therapeutics announces U.S. FDA clearance of IND for CT7439, a first-in-class inhibitor of CDK12/13. News release. Carrick Therapeutics. September 7, 2023. Accessed September 7, 2023. https://bit.ly/3Z9GoN9
  2. Leeman JE, Shin KY, Chen YH, et al. Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: a systematic review and meta-analysis. Cancer. Published online July 24, 2023. doi:10.1002/cncr.34836
  3. Sanft T, Harrigan M, McGowan C, et al. Randomized trial of exercise and nutrition on chemotherapy completion and pathologic complete response in women with breast cancer: the lifestyle, exercise, and nutrition early after diagnosis study. J Clin Oncol. Published online September 1, 2023. doi:10.1200/JCO.23.00871
  4. Whelan TJ, Smith S, Parpia S, et al. Omitting radiotherapy after breast-conserving surgery in luminal A breast cancer. N Engl J Med. 2023;389:612-619. doi:10.1056/NEJMoa2302344
Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Related Content
Investigators from the United States, United Kingdom, Canada, and Germany look to conduct a primary prevention trial in patients with Li-Fraumeni syndrome.

Forming International Collaborative Efforts to Assess Metformin Use in LFS

Russ Conroy
October 24th 2024
Article

Investigators from the United States, United Kingdom, Canada, and Germany look to conduct a primary prevention trial in patients with Li-Fraumeni syndrome.

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Improving Quality of Life in Cancer With Physical Medicine & Rehabilitation

Jessica Cheng, MD
September 9th 2024
Podcast

Jessica Cheng, MD, highlights how physical medicine and rehabilitation may help optimize function and performance status in patients with cancer.

Breast Cancer Breakthroughs: 2024 ESMO Highlights

Breast Cancer Breakthroughs: 2024 ESMO Highlights

Neil M. Iyengar, MD
October 21st 2024
Article

Neil M. Iyengar, MD, highlighted the most important data in breast cancer to come from 2024 ESMO.

Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.

Taking a “Cross-Cutting Approach” With Cancer Vaccinations

Catherine J. Wu, MD
August 12th 2024
Podcast

Cancer vaccines may pair well with other forms of immunotherapy in the treatment of patients with cancer, according to Catherine J. Wu, MD.

Pathogenic Variants Lead to Better Attitudes, Engagement in Genetic Testing | Image Credit: © Siarhei - stock.adobe.com.

Pathogenic Variants Lead to Better Attitudes, Engagement in Genetic Testing

Ariana Pelosci
October 18th 2024
Article

Those with pathogenic variants had a higher likelihood of communicating with clinicians and family members about test results.

Bin Gui, MD, discussed how ultra-hypofractionated radiotherapy may be a convenient treatment option for elderly patients with early breast cancer.

Ultra-Hypofractionated RT Shows Control, Tolerability in Elderly Breast Cancer

Russ Conroy
October 17th 2024
Article

Bin Gui, MD, discussed how ultra-hypofractionated radiotherapy may be a convenient treatment option for elderly patients with early breast cancer.